Weekender 9/9/16

In tribute to our industry as well as New Jersey, BioNJ and our 4th Annual CEO Summit, BioNJ’s President and CEO, Debbie Hart; Lt. Governor Kim Guadagno; along with Board members and other industry members had the honor yesterday of ringing the opening bell of the NASDAQ. The opening was featured on four national news… Read the full article


Weekender 8/26/16

Many of New Jersey’s innovative biopharma companies advanced recently on their way to new FDA drug approvals, including BioNJ Members Scynexis, Soligenix and Eli Lilly & Co., giving fresh hope to Patients and their families around the world. Because Patients Can’t WaitSM, BioNJ is excited for our fall lineup of events — bringing together the… Read the full article


Weekender 8/12/16

In this week’s edition of the BioLines Weekender we introduce a new section entitled “Economic Developments.” In addition to highlighting the numerous companies moving to the Garden State, we will be spotlighting those expanding their footprint, such as BioNJ Member Allergan. This week, Allergan announced that its new U.S. Administrative Headquarters, expected to be completed… Read the full article


Weekender 7/29/16

Hope for Patients Around the World… New Jersey companies once again are represented at the global forefront of developing important drugs to meet significant unmet medical needs, as recognized in recent announcements from Janssen Therapeutics, Sanofi, Eli Lilly and Company and Eisai. Enjoy this week’s edition of the BioLines Weekender chock full of stories of… Read the full article


Weekender 7/15/16

BREAKING NEWS A big legislative win — G.M.O. Labeling Bill gains House approval. Click here to read the full article. Welcome to this week’s edition of the BioLines Weekender filled with stories of hope for patients around the globe. Delivering life-changing therapies and cures, New Jersey’s medical innovation and drug development and commercialization capabilities are… Read the full article


Weekender 7/1/16

This week’s edition of the BioLines Weekender features lots of advances in the New Jersey ecosystem, including BioNJ Member The Medicines Company’s announcement that its investigational antibiotic, CARBAVANCE® (meropenem-vaborbactam), met both FDA and EMA pre-specified primary endpoints in the Phase 3 TANGO 1 clinical trial in patients with cUTI. Congrats to The Medicines Company Team… Read the full article


Weekender 6/17/16

Patients will be served with the announcement of BioNJ Member Amicus Therapeutics’ EU approval for the use of Galafold (Migalastat) in patients with Fabry Disease. Congratulations to John Crowley and BioNJ Board Member Bradley Campbell and the entire Amicus team. Another grand New Jersey success story! Meanwhile New Jersey was well represented in San Francisco… Read the full article


Weekender 6/3/16

We kick off this week’s edition of the BioLines Weekender with a moving and meaningful video of “Magic” Max Schill, our 7-year old patient advocate, who continues to work toward the passage of the Senate’s version of the 21st Century Cures Act. Click here for Max’s video on why #CuresNow not tomorrow. A number of… Read the full article


Weekender 5/20/16

New Jersey’s dynamic life sciences ecosystem is in the national spotlight once again, featured in Bio Business magazine’s article, entitled Growing in the Garden State: Here’s Why Big Pharma has Put Down Roots in New Jersey. The editorial touts New Jersey as “…fertile ground for biotechnology and pharmaceutical companies looking to move from proof of… Read the full article


Weekender 5/6/16

New Jersey/New York ranks #3 on Genetic Engineering News’ “Top 10 U.S. Biopharma Clusters.“ GEN ranks New Jersey/NewYork region as third in the country and reports that New Jersey represents more than half of the region’s total lab space and accounts for 60% of the region’s industry jobs thanks to the State’s heritage pharma industry… Read the full article